Huntington’s disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases

@article{Truant2008HuntingtonsDR,
  title={Huntington’s disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases},
  author={Ray Truant and Randy Singh Atwal and Carly R. Desmond and Lise N. Munsie and Thu L Tran},
  journal={The FEBS Journal},
  year={2008},
  volume={275}
}
After the successful cloning of the first gene for a polyglutamine disease in 1991, the expanded polyglutamine tract in the nine polyglutamine disease proteins became an obvious therapeutic target. Early hypotheses were that misfolded, precipitated protein could be a universal pathogenic mechanism. However, new data are accumulating on Huntington’s disease and other polyglutamine diseases that appear to contradict the toxic aggregate hypothesis. Recent data suggest that the toxic species of… 
View on Wiley
onlinelibrary.wiley.com
107 Citations
Highly Influential Citations
3
Background Citations
49
Methods Citations
2

107 Citations

Conformational studies of pathogenic expanded polyglutamine protein deposits from Huntington’s disease

Recent developments in the structural biology of polyglutamine-expanded huntingtin fragments, and especially the contributions enabled by advances in solid-state nuclear magnetic resonance spectroscopy, are examined.

Huntington's disease: From molecular basis to therapeutic advances.

Molecular biology of Huntington's disease.

Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies.

Huntington's disease: from molecular pathogenesis to clinical treatment

Analysis of Huntingtin Protein Aggregation Mechanisms and the Development of a Clinically-Derived Human Cell Model of Huntington's Disease

This thesis presents a culmination of several projects that focus on disease modelling, primarily outlining phenotypic differences between wildtype and HD cells that will benefit the understanding of disease pathogenesis and generated novel, clinically-relevant human patient fibroblast cell lines and characterized several disease phenotypes.

Advances in Huntington Disease Drug Discovery

How cellular systems are being used to investigate HD biology as well as to identify mechanisms with therapeutic potential are described, including screening using electrophysiological endpoints.

A stable G‐quartet binds to a huntingtin protein fragment containing expanded polyglutamine tracks

The data support the notion that G20 exhibits some selectivity in binding to specific protein species that assemble along the aggregation pathway, which is linked to intracellular aggregates that form because of the tendency of the mutant protein to misfold.

Huntington's disease: The current state of research with peripheral tissues

Huntington’s Disease Studies at the Interface of Chemistry, Physics, and Biology

Huntington’s disease (HD) is a uniformly fatal genetic disease causing progressive degeneration of the central nervous system in approximately 250,000 people worldwide. Unlike other neurodegenerative…
...

68 References

Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease

A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.

A yeast-based high-throughput screening assay is used to identify small-molecule inhibitors of polyQ aggregation that represent four primary chemical scaffolds and are strong lead compounds for the development of therapeutics for human polyQ diseases.

A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure.

The data found support in the context of the htt exon-1 N-terminal fragment in both mammalian cell culture and cultured primary cortical neurons provide a better understanding of the structural basis of polyQ aggregation in toxicity in HD.

Oligoproline effects on polyglutamine conformation and aggregation.

A Rapid Cellular FRET Assay of Polyglutamine Aggregation Identifies a Novel Inhibitor

Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.

It is demonstrated that compounds that increase inclusion formation may actually lessen cellular pathology in both Huntington's and Parkinson's diseases, suggesting a therapeutic approach for neurodegenerative diseases caused by protein misfolding.

SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein.

A novel spinocerebellar ataxia (SCA) form in four Japanese pedigrees is identified which is caused by an abnormal CAG expansion in the TATA-binding protein (TBP) gene, a general transcription initiation factor, and it has been added to the group of polyglutamine diseases.

Amyloid diseases: abnormal protein aggregation in neurodegeneration.

This review will focus on biophysical studies of protein aggregation in AD and FAP, where mechanistic models connecting pathological and genetic data to clinical disease are beginning to emerge.

Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice

Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis

These results reveal markedly divergent mobility states for an expanded polyglutamine protein, ataxin-3, and establish that nuclear inclusions formed by this protein are aggregates, which may help explain disease-specific elements of pathogenesis in these neurodegenerative disorders.
...